



Annual General Meeting of Ipsen S.A. of 21 May 2025

» *Voting results*

PARIS, FRANCE, 22 May 2025

Number of shares comprising the capital	83,814,526
Number of shares with voting rights	82,705,638
Number of shareholders present, represented or voting by mail	2,776
Number of shares held by shareholders present, represented or voting by mail	69,438,838
Number of votes held by shareholders present, represented or voting by mail	117,140,811
Quorum	83.96%

Resolutions	Total number of votes cast	Number of shares	% of capital cast	Votes for		Votes against		Votes not validly cast			Result
				Number	%	Number	%	Abstention	Void	Not voted	
As an Ordinary Annual General Meeting											
1. Approval of the annual financial statements for the financial year ending 31 December 2024	116,993,178	69,438,838	82.67%	116,967,698	99.98%	25,480	0.02%	147,628	0	5	Adopted
2. Approval of the consolidated financial statements for the financial year ending on 31 December 2024	116,993,178	69,438,838	82.67%	116,967,698	99.98%	25,480	0.02%	147,628	0	5	Adopted
3. Allocation of the results for the 2024 financial year and setting of the dividend at €1.40 per share	117,139,572	69,438,838	82.85%	117,138,856	>99.99%	716	<0.01%	1,234	0	5	Adopted
4. Special report of the statutory auditors on regulated agreements – Finding of absence of new agreement	117,134,463	69,438,838	82.84%	117,134,155	>99.99%	308	<0.01%	6,343	0	5	Adopted
5. Renewal of the term of office of Mr. David LOEW as a Director	117,076,095	69,438,838	82.77%	115,688,760	98.82%	1,387,335	1.18%	64,711	0	5	Adopted
6. Renewal of the term of office of Mr. Antoine FLOCHEL as a Director	117,138,123	69,438,838	82.85%	98,680,566	84.24%	18,457,557	15.76%	2,683	0	5	Adopted
7. Renewal of the term of office of Mrs. Margaret LIU as a Director	117,065,831	69,438,838	82.76%	116,101,523	99.18%	964,308	0.82%	74,975	0	5	Adopted
8. Renewal of the term of office of Mrs. Karen WITTS as a Director	117 081 023	69 438 838	82,78%	113 551 550	96,99%	3 529 473	3,01%	59 783	0	5	Adopted
9. Annual fixed amount to be allocated to the members of the Board of Directors	117,128,527	69,438,838	82.84%	116,947,708	99.85%	180,819	0.15%	12,279	0	5	Adopted
10. Approval of the compensation policy applicable to the members of the Board of Directors	117,134,419	69,438,838	82.84%	116,943,269	99.84%	191,150	0.16%	6,387	0	5	Adopted

11. Approval of the compensation policy applicable to the Chairman of the Board of Directors	117,134,219	69,438,838	82.84%	116,993,448	99.88%	140,771	0.12%	6,487	0	105	Adopted
12. Approval of the compensation policy applicable to the Chief Executive Officer and/or any other executive officer	117,132,803	69,438,838	82.84%	96,867,370	82.70%	20,265,433	17.30%	8,003	0	5	Adopted
13. Approval of the information relating to the compensation of corporate officers referred to in I of Article L.22-10-9 of the French Commercial Code	117,138,972	69,438,838	82.85%	114,996,217	98.17%	2,142,755	1.83%	1,834	0	5	Adopted
14. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. Marc de GARIDEL, Chairman of the Board of Directors	117,134,687	69,438,838	82.84%	116,987,669	99.87%	147,018	0.13%	6,119	0	5	Adopted
15. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. David LOEW, Chief Executive Officer	116,933,701	69,438,838	82.60%	113,357,087	96.94%	3,576,614	3.06%	207,105	0	5	Adopted
16. Authorization to be given to the Board of Directors to allow the Company to repurchase its own shares pursuant to the provisions of article L.22-10-62 of the French Commercial Code	117,123,546	69,438,838	82.83%	117,064,937	99.95%	58,609	0.05%	17,260	0	5	Adopted
17. Ratification of the transfer of the registered office from 65 quai Georges Gorse – 92100 Boulogne-Billancourt to 70 rue Balard, 75015 Paris	117,108,806	69,438,838	82.81%	117,108,004	>99.99%	802	<0.01%	32,000	0	5	Adopted
As an Extraordinary Annual General Meeting											
18. Authorization to be given to the Board of Directors to cancel the shares repurchased by the Company pursuant to Article L. 22-10-62 of the French Commercial Code, duration of authorization, ceiling	117,139,328	69,438,838	82.85%	117,066,277	99.94%	73,051	0.06%	1,478	0	5	Adopted
19. Delegation of authority to be given to the Board of Directors to increase the capital by incorporating reserves, profits and/or premiums, duration of the delegation, maximum nominal amount of the capital increase, treatment of fractional shares, suspension during a public offering period	117,139,331	69,438,838	82.85%	117,058,236	99.93%	81,095	0.07%	1,475	0	5	Adopted

20. Delegation of authority to be given to the Board of Directors to issue ordinary shares and/or securities giving access to the capital (of the Company or a Group company) and/or debt securities, with retention of preferential subscription rights, duration of the delegation, maximum nominal amount of the capital increase, right to offer unsubscribed shares to the public, suspension during a public offering period	114,406,254	69,438,838	79.59%	113,433,297	99.15%	972,957	0.85%	2,734,552	0	5	Adopted
21. Delegation of authority to the Board of Directors to issue ordinary shares and/or securities giving right to the capital (of the Company or a Group company) and/or debt securities, without preferential subscription right by public offer (to the exclusion of offers referred to in 1 of Article L.411-2 of the French Monetary and Financial Code), and/or as consideration for securities in connection with a public exchange offer, duration of the delegation, maximum nominal amount of the capital increase, issue price, option to limit the issue to the amount of subscriptions or to allocate unsubscribed securities, suspension during a public offering period	117,134,371	69,438,838	82.84%	99,656,162	85.08%	17,478,209	14.92%	6,435	0	5	Adopted
22. Delegation of authority to the Board of Directors to issue ordinary shares and/or securities giving right to the capital (of the Company or a Group company) and/or debt securities, without preferential subscription rights by an offering under the meaning of 1 of Article L.411-2 of the French Monetary and Financial Code, duration of the delegation, maximum nominal amount of the capital increase, issue price, option to limit the issue to the amount of subscriptions or to allocate unsubscribed securities, suspension during a public offering period	117,110,304	69,438,838	82.81%	98,491,277	84.10%	18,619,027	15.90%	30,502	0	5	Adopted
23. Authorization to increase the amount of issues	117,035,266	69,438,838	82.72%	98,357,609	84.04%	18,677,657	15.96%	105,540	0	5	Adopted
24. Delegation to be given to the Board of Directors to increase the share capital by issuance of ordinary shares and/or securities giving rights to the share capital, within the limit of 10% of the share capital, in order to pay for capital contributions in kind consisting of equity securities or securities giving rights to the share capital, duration of the delegation, suspension during a takeover bid	117,138,975	69,438,838	82.85%	113,641,887	97.01%	3,497,088	2.99%	1,831	0	5	Adopted

25. Delegation of authority to be given to the Board of Directors to increase the share capital by issuance of ordinary shares without preferential subscription rights in favor of members of a company savings plan pursuant to Articles L.3332-18 et seq. of the French Labor Code, duration of the delegation, maximum nominal amount of the share capital increase, issue price, possibility to allocate free shares in compliance with Article L.3332-21 of the French Labor Code	117,139,186	69,438,838	82.85%	115,213,319	98.36%	1,925,867	1.64%	1,620	0	5	Adopted
26. Authorization to be given to the Board of Directors to grant stock options to subscribe to and/or to purchase shares to salaried staff members and/or certain company officers of the Company or of affiliated companies or economic interest groups, shareholders' waiver of their preferential subscription rights, duration of the authorization, ceiling, exercise price, maximum term of the option	117,139,165	69,438,838	82.85%	100,185,919	85.53%	16,953,246	14.47%	1,641	0	5	Adopted
27. Amendment of article 16.2 of the Articles of Association concerning the written consultation of Directors	117,138,043	69,438,838	82.85%	117,133,435	>99.99%	4,608	<0.01%	2,763	0	5	Adopted
28. Amendment of article 16.3 of the Articles of Association concerning the use of telecommunication facilities at Board meetings	117,136,026	69,438,838	82.84%	117,129,170	>99.99%	6,856	<0.01%	4,780	0	5	Adopted
29. Amendment of article 26.4 of the Articles of Association concerning the use of telecommunication facilities at Shareholders meetings	117,136,026	69,438,838	82.84%	116,897,243	99.80%	238,783	0.20%	4,780	0	5	Adopted
As an Ordinary Annual General Meeting											
30. Powers to carry out formalities	117,136,183	69,438,838	82.84%	117,135,646	>99.99%	537	<0.01%	4,411	0	217	Adopted

ENDS

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipsen.com](https://www.ipsen.com).

Ipsen contacts

Investors

» Khalid DEOJEE | + 33 6 66 01 95 26 | khalid.deojee@ipsen.com

Media

» Sally BAIN | + 1 857 320 0517 | sally.bain@ipsen.com

» Anne LIONTAS | + 33 7 67 34 72 96 | anne.liontas.ext@ipsen.com

Disclaimers and/or Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results

obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipсен.com.